MXPA04007516A - Derivados de dihidrobenzodiazepin-2-ona para tratamiento de enfermedades neurologicas. - Google Patents

Derivados de dihidrobenzodiazepin-2-ona para tratamiento de enfermedades neurologicas.

Info

Publication number
MXPA04007516A
MXPA04007516A MXPA04007516A MXPA04007516A MXPA04007516A MX PA04007516 A MXPA04007516 A MX PA04007516A MX PA04007516 A MXPA04007516 A MX PA04007516A MX PA04007516 A MXPA04007516 A MX PA04007516A MX PA04007516 A MXPA04007516 A MX PA04007516A
Authority
MX
Mexico
Prior art keywords
phenyl
pyridin
methyl
mmol
trifluoromethyl
Prior art date
Application number
MXPA04007516A
Other languages
English (en)
Spanish (es)
Inventor
Wichmann Juergen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04007516A publication Critical patent/MXPA04007516A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA04007516A 2002-02-06 2003-01-28 Derivados de dihidrobenzodiazepin-2-ona para tratamiento de enfermedades neurologicas. MXPA04007516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06
PCT/EP2003/000859 WO2003066623A1 (en) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
MXPA04007516A true MXPA04007516A (es) 2004-11-10

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04007516A MXPA04007516A (es) 2002-02-06 2003-01-28 Derivados de dihidrobenzodiazepin-2-ona para tratamiento de enfermedades neurologicas.

Country Status (30)

Country Link
US (1) US6949542B2 (enExample)
EP (1) EP1474416B1 (enExample)
JP (1) JP4077411B2 (enExample)
KR (1) KR20040081486A (enExample)
CN (1) CN100497333C (enExample)
AR (1) AR038481A1 (enExample)
AT (1) ATE374196T1 (enExample)
AU (1) AU2003205695B8 (enExample)
BR (1) BR0307474A (enExample)
CA (1) CA2474219C (enExample)
DE (1) DE60316538T2 (enExample)
DK (1) DK1474416T3 (enExample)
ES (1) ES2294264T3 (enExample)
GT (1) GT200300028A (enExample)
HR (1) HRP20040678A2 (enExample)
IL (1) IL163102A (enExample)
MX (1) MXPA04007516A (enExample)
MY (1) MY176608A (enExample)
NO (1) NO327697B1 (enExample)
NZ (1) NZ534122A (enExample)
PA (1) PA8565901A1 (enExample)
PE (1) PE20031011A1 (enExample)
PL (1) PL372425A1 (enExample)
PT (1) PT1474416E (enExample)
RU (1) RU2315764C2 (enExample)
SI (1) SI1474416T1 (enExample)
TW (1) TWI326599B (enExample)
UY (1) UY27654A1 (enExample)
WO (1) WO2003066623A1 (enExample)
ZA (1) ZA200406032B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203294A3 (en) * 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR101151993B1 (ko) * 2007-04-19 2012-06-01 에프. 호프만-라 로슈 아게 다이하이드로-벤조[b][1,4]다이아제핀-2-온 설폰아미드 유도체
BRPI0815696A2 (pt) 2007-08-27 2016-06-21 Hoffmann La Roche composto derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, metódo para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr e uso destes compostos.
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
EP2205565B1 (en) 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ601483A (en) 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130424A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
KR20120065360A (ko) 2009-08-21 2012-06-20 오츠카 세이야쿠 가부시키가이샤 벤조[b][1,4]디아제핀-2,4-디온 화합물의 제조 방법
BR112012018500A2 (pt) 2010-01-25 2016-08-16 Chdi Foundation Inc alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2834548C (en) * 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2013033246A2 (en) 2011-08-29 2013-03-07 Braincells, Inc. Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
PT2750677T (pt) 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 mglu2/3 길항제
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
JP2017520610A (ja) 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション,インコーポレーテッド Hiv関連障害を治療するための方法及び組成物
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ[1,5−d][1,4]オキサゼピン化合物(TETRAHYDROIMIDAZO[1,5−d][1,4]OXAZEPINECOMPOUND)
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008906T2 (de) * 1989-03-23 1994-08-25 Pfizer Antiallergische Mittel auf der Basis von Diazepin.
RU2259360C2 (ru) 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
HUP0203294A3 (en) 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
DE60316538T2 (de) 2008-08-21
CN1633430A (zh) 2005-06-29
US6949542B2 (en) 2005-09-27
CA2474219A1 (en) 2003-08-14
US20030166639A1 (en) 2003-09-04
JP2005522440A (ja) 2005-07-28
SI1474416T1 (sl) 2008-02-29
DE60316538D1 (de) 2007-11-08
PL372425A1 (en) 2005-07-25
NO327697B1 (no) 2009-09-14
TWI326599B (en) 2010-07-01
ATE374196T1 (de) 2007-10-15
DK1474416T3 (da) 2008-01-14
EP1474416A1 (en) 2004-11-10
PT1474416E (pt) 2007-12-27
UY27654A1 (es) 2003-08-29
HK1078858A1 (zh) 2006-03-24
WO2003066623A1 (en) 2003-08-14
AR038481A1 (es) 2005-01-19
AU2003205695A1 (en) 2003-09-02
RU2004126945A (ru) 2005-06-27
IL163102A (en) 2011-07-31
EP1474416B1 (en) 2007-09-26
CA2474219C (en) 2010-04-13
AU2003205695B8 (en) 2008-05-01
NZ534122A (en) 2006-12-22
NO20043237L (no) 2004-08-02
PA8565901A1 (es) 2003-09-05
AU2003205695B2 (en) 2008-04-03
ES2294264T3 (es) 2008-04-01
ZA200406032B (en) 2005-10-12
BR0307474A (pt) 2004-11-09
GT200300028A (es) 2004-06-11
KR20040081486A (ko) 2004-09-21
HRP20040678A2 (en) 2005-10-31
MY176608A (en) 2020-08-18
PE20031011A1 (es) 2003-11-29
TW200302730A (en) 2003-08-16
JP4077411B2 (ja) 2008-04-16
RU2315764C2 (ru) 2008-01-27
CN100497333C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
MXPA04007516A (es) Derivados de dihidrobenzodiazepin-2-ona para tratamiento de enfermedades neurologicas.
KR100566171B1 (ko) mGluR2 길항제 Ⅱ인디하이드로-벤조[b][1,4]디아제핀-2-온 유도체
KR100566178B1 (ko) mGluR2 길항물질 I로서의디하이드로-벤조[b][1,4]디아제핀-2-온 유도체
AU2002312788A1 (en) Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
WO2009143039A2 (en) Heterocyclic compounds as factor ixa inhibitors
WO2005023782A1 (ja) 置換された縮環ピリミジン-4(3h)-オン化合物
JP2024521657A (ja) ポロ様キナーゼ4阻害剤
HK1078858B (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders

Legal Events

Date Code Title Description
FG Grant or registration